Two phase 2 clinical trials were conducted to study the PARP inhibitor olaparib’s use in combination with durvalumab (NCT03991832) and ceralasertib (NCT03878095) to treat IDH-mutant cholangiocarcinoma [49,50]. The gene discussed is IDH2; the disease is cholangiocarcinoma.